For the fiscal year ended December 31, 2019
|
Commission file number 001-38286
|
Delaware
|
95-4484725
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
5000 Research Court, Suite 750, Suwanee, Georgia
|
30024
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of Each Class
|
Trading Symbol
|
Name of Each Exchange On Which Registered
|
Common Stock $0.01 par value per share
|
AMRH
|
The NASDAQ Stock Market LLC
|
Warrants to Purchase Common Stock
|
AMRHW
|
The NASDAQ Stock Market LLC
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
|
Non-accelerated filer
|
☒
|
Smaller reporting company
|
☒
|
|
Emerging growth company
|
☒
|
Item 1.
|
1
|
|
Item 1A.
|
9 | |
Item 1B.
|
27
|
|
Item 2.
|
27 | |
Item 3.
|
27 | |
Item 4.
|
27 | |
Item 5.
|
28 | |
Item 6.
|
28
|
|
Item 7.
|
29
|
|
Item 7A.
|
37
|
|
|
||
Item 8.
|
37 | |
|
||
Item 9.
|
37 | |
|
||
Item 9A.
|
37 | |
|
||
Item 9B.
|
39 | |
|
||
Item 10.
|
39
|
|
|
||
Item 11.
|
42
|
|
|
||
Item 12.
|
45
|
|
|
||
Item 13.
|
46
|
|
|
||
Item 14.
|
46
|
|
|
||
Item 15.
|
48
|
|
F-1
|
•
|
the approval of each of the Company’s and Jay Pharma’s shareholders;
|
•
|
the consummation of the Spin-Off;
|
•
|
the entering into of certain ancillary agreements by and between the Company and ExchangeCo;
|
•
|
the approval of the NASDAQ to approve for listing the common stock of the resulting company.
|
Characteristic
|
Description
|
|
Mature Market
|
• Most large global companies have already outsourced what they wanted to outsource.
|
|
Commoditized Business Model
|
• North America and Europe continue to be the markets with attractive spending potential. However, increased
regulations and visa dependencies prove to be a major drawback of the model.
|
|
• The benefits realized from the business model are largely based on labor arbitrage, productivity
benefits and portfolio restructuring. These contours have changed due to commoditization.
|
||
Insourcing
|
• Extremely rapid changes in technology are forcing IT services–traditionally an outsourcing business—to adopt an
insourcing model.
|
|
Rapid Technology Shifts
|
• Cloud services, robotic process automation, artificial intelligence and internet of things are increasingly in
demand as part of outsourcing engagements. Smart robots increasingly operate in the cloud, and a ‘labor-as-a-service’ approach has emerged, as clients and providers find that intelligent tools and virtual agents can be easily and flexibly
hosted on cloud platforms.
|
|
• Social media, cloud computing, mobility and big data will continue to be mainstays for any IT
ecosystem.
|
||
• The convergence of cloud computing, virtualization (applications and infrastructure) and
utility computing is around the corner. The ability of a vendor to offer an integrated basket of services on a SaaS model, will be a key differentiator.
|
||
• Enterprises are becoming more digital. There is a strong convergence of human and machine
intelligence thanks to drivers like advanced sensors and machine learning. Operations and technology are converging.
|
||
Contracts & Decision Making
|
• Large multi-year contracts will be renegotiated and broken down into shorter duration contracts and will involve
multiple vendors rather than sole sourcing.
|
|
• The ability to demonstrate value through Proof of Concepts (POCs) and willingness to offer
outcome based pricing are becoming critical considerations for decision making, Requests for Proposal (RFP)-driven decisions are increasingly rare.
|
●
|
The alignment of SAP to enterprises is extremely strong. Given the reliance of enterprises on applications, clients tend to make long-term bets on SAP as an enterprise solution.
|
●
|
According to the September 2014 “HfS Blueprint Report” from by HfS Research Ltd., the SAP market is a multi-billion-dollar market that is very fragmented (there are over 5,000 consulting firms), with the
three largest service providers capturing an increasing share of the market.
|
●
|
A significant number of SAP customers must move to S/4 HANA by 2025.
|
|
• |
well-developed recruiting, training and retention model;
|
|
• |
successful service delivery model;
|
|
• |
broad referral base;
|
|
• |
continual investment in process improvement and knowledge capture;
|
|
• |
investment in research and development;
|
|
• |
strong corporate governance; and
|
|
• |
custom strategic partnerships to provide breadth and depth of services.
|
If the requirements of our indebtedness are not satisfied, a default could be deemed to occur and our lenders or the holders of our notes could accelerate the payment of the outstanding indebtedness.
As of December 31, 2019, we had an outstanding aggregate of $1 million in 8% Convertible Unsecured Promissory Notes (the “2017 Notes”), which were issued to one of our accredited investor, including one of the Company’s then-directors, Dhruwa N. Rai, and David Luci, who became a director of the Company in February 2018. The 2017 Notes bear interest at 8% per annum and matured in March 2020. We have not repaid the 2017 Notes and do not currently have sufficient funds available to meet these obligations.
●
|
establishing and maintaining broad market acceptance of our solutions and services and converting that acceptance into direct and indirect sources of revenue;
|
●
|
establishing and maintaining adoption of our technology solutions in a wide variety of industries and on multiple enterprise architectures;
|
●
|
timely and successfully developing new solutions and services and increasing the functionality and features of existing solutions and services;
|
●
|
developing solutions and services that result in high degree of enterprise client satisfaction and high levels of end-customer usage;
|
●
|
successfully responding to competition, including competition from emerging technologies and solutions;
|
●
|
developing and maintaining strategic relationships to enhance the distribution, features, content and utility of our solutions and services; and
|
●
|
identifying, attracting and retaining talented personnel at reasonable market compensation rates in the markets in which we employ.
|
·
|
financial difficulties for a client;
|
·
|
a change in strategic priorities, resulting in a reduced level of technology spending;
|
·
|
a demand for price reductions; or an unwillingness to accept higher pricing due to various factors such as higher wage costs, higher cost of doing business;
|
·
|
a change in outsourcing strategy by moving more work to the client’s in-house technology departments or to our competitors;
|
·
|
the replacement by our clients of existing software with packaged software supported by licensors;
|
·
|
mergers and acquisitions;
|
·
|
consolidation of technology spending by a client, whether arising out of mergers and acquisitions, or otherwise; and
|
·
|
sudden ramp-downs in projects due to an uncertain economic environment.
|
●
|
make it difficult for us to obtain financing in the future for acquisitions, working capital, capital expenditures, debt service requirements or other purposes;
|
●
|
limit our flexibility in planning for or reacting to changes in our business;
|
●
|
limit our ability to pay dividends;
|
●
|
make us more vulnerable in the event of a downturn in our business; and
|
●
|
affect certain financial covenants with which we must comply in connection with our credit facilities.
|
●
|
technological innovations or new products and services by us or our competitors;
|
●
|
additions or departures of key personnel;
|
●
|
sales of our common stock, including management shares;
|
●
|
limited availability of freely-tradable “unrestricted” shares of our common stock to satisfy purchase orders and demand;
|
●
|
our ability to execute our business plan;
|
●
|
operating results that fall below expectations;
|
●
|
loss of any strategic relationship;
|
●
|
industry developments;
|
●
|
economic and other external factors;
|
●
|
our ability to manage the costs of maintaining adequate internal financial controls and procedures in connection with the acquisition of additional businesses; and
|
●
|
period-to-period fluctuations in our financial results.
|
●
|
are not required to obtain an attestation and report from our auditors on our management’s assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002;
|
●
|
are not required to provide a detailed narrative disclosure discussing our compensation principles, objectives and elements and analyzing how those elements fit with our principles and objectives (commonly
referred to as “compensation discussion and analysis”);
|
●
|
are not required to obtain a non-binding advisory vote from our stockholders on executive compensation or golden parachute arrangements (commonly referred to as the “say-on-pay,” “say-on-frequency” and
“say-on-golden-parachute” votes);
|
●
|
are exempt from certain executive compensation disclosure provisions requiring a pay-for-performance graph and CEO pay ratio disclosure;
|
●
|
may present only two years of audited financial statements and only two years of related Management’s Discussion & Analysis of Financial Condition and Results of Operations (“MD&A”); and
|
●
|
are eligible to claim longer phase-in periods for the adoption of new or revised financial accounting standards under §107 of the JOBS Act.
|
●
|
no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;
|
●
|
the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death, or removal of a director, which prevents
stockholders from being able to fill vacancies on our board of directors;
|
●
|
the ability of our board of directors to determine whether to issue shares of our preferred stock and to determine the price and other terms of those shares, including preferences and voting rights,
without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;
|
●
|
limiting the liability of, and providing indemnification to, our directors and officers;
|
●
|
controlling the procedures for the conduct and scheduling of stockholder meetings; and
|
●
|
advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders’
meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of the Company.
|
•
|
Ameri’s or Jay Pharma’s current and prospective employees could experience uncertainty about their future roles within the resulting company; and, this uncertainty might adversely affect
Ameri’s or Jay Pharma’s ability to retain, recruit and motivate key personnel;
|
•
|
the attention of Ameri’s or Jay Pharma’s management may be directed towards the completion of the amalgamation and other transaction-related considerations and may be diverted from the day-to-day business operations of Ameri or Jay
Pharma, as applicable, and matters related to the amalgamation may require commitments of time and resources that could otherwise have been devoted to other opportunities that might have been beneficial to Ameri or Jay Pharma, as
applicable;
|
•
|
customers, prospective customers, suppliers, collaborators and other third parties with business relationships with Ameri or Jay Pharma may decide not to renew or may decide to seek to terminate, change or renegotiate their
relationships with Ameri or Jay Pharma as a result of the amalgamation, whether pursuant to the terms of their existing agreements with Ameri or Jay Pharma; and
|
|
• |
Completion of preclinical laboratory tests, animal studies, and formulation studies according to Good Laboratory Practices and other applicable regulations;
|
|
• |
Submission to the FDA of an Investigational New Drug Application, or an “IND,” which must become effective before human clinical trials may begin in the United States;
|
|
• |
Performance of adequate and well-controlled human clinical trials according to the FDA’s current good clinical practices, or GCPs, which sufficiently demonstrate the safety and efficacy of the proposed drug or biologic for its
intended uses;
|
|
• |
Submission to the FDA of a New Drug Application, or an NDA, for a new drug product;
|
|
• |
Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug or biologic is to be produced to assess compliance with the FDA’s current good manufacturing practice standards, or cGMP, to
assure that the facilities, methods and controls are adequate to preserve the drug’s or biologic’s identity, strength, quality and purity;
|
|
• |
Potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the NDA or biologics license application; and
|
|
• |
FDA review and, potentially, approval of the NDA.
|
•
|
Our ability to enter into additional technology-management and consulting agreements, to diversify our client base and to expand the geographic areas we serve;
|
•
|
Our ability to attract competent, skilled professionals and on-demand technology partners for our operations at acceptable prices to manage our overhead;
|
•
|
Our ability to acquire other technology services companies and integrate them with our existing business;
|
•
|
Our ability to raise additional equity capital, if and when we needed;
|
•
|
We may incur an impairment of the goodwill acquired from our prior business acquisitions if our acquired entities do not experience growth; and
|
•
|
Our ability to control our costs of operation as we expand our organization and capabilities.
|
Twelve Months
Ended December 31,
|
||||||||
2019
|
|
2018 | ||||||
Net revenue
|
$
|
39,914,675
|
|
$
|
42,998,280
|
|||
Cost of revenue
|
31,763,955
|
34,014,776
|
||||||
Gross profit
|
8,150,720
|
8,983,504
|
||||||
Operating expenses:
|
||||||||
Selling, general and administration
|
12,210,317
|
10,794,822
|
||||||
Depreciation and amortization
|
2,265,297
|
2,903,662
|
||||||
Acquisition related expenses
|
-
|
333,237
|
||||||
Changes in estimate for consideration payable
|
-
|
(6,940,310
|
)
|
|||||
Impairment charges on goodwill and intangible assets
|
-
|
9,038,553
|
||||||
Operating expenses
|
14,475,614
|
16,129,964
|
||||||
Operating Income (loss):
|
(6,324,894
|
)
|
(7,146,460
|
)
|
||||
Interest expense
|
(691,138
|
)
|
(729,896
|
)
|
||||
Other income
|
4,540
|
88,161
|
||||||
Change in fair value of warrant liability
|
1,796,174
|
(2,760,819
|
)
|
|||||
Total other income /(expenses)
|
1,109,576
|
(3,402,554
|
)
|
|||||
Income (loss) before income taxes
|
(5,215,318
|
)
|
(10,549,014
|
)
|
||||
Income tax benefit
|
(388,657
|
)
|
(6,348,502
|
)
|
||||
Net Income (loss)
|
(5,603,975
|
)
|
(16,897,516
|
)
|
||||
Dividend on preferred stock
|
(426,003
|
)
|
(2,583,185
|
)
|
||||
Net (loss) attributable to common stock holders
|
(6,029,978
|
)
|
(19,480,701
|
)
|
||||
Other comprehensive income/ (loss), net of tax:
|
||||||||
Foreign exchange translation adjustment
|
(26,985
|
)
|
50,122
|
|||||
Total comprehensive income (loss)
|
$
|
(6,056,963
|
)
|
(19,430,579
|
)
|
|||
Comprehensive (loss) attributable to the Company
|
(6,056,963
|
)
|
(19,430,579
|
)
|
||||
Comprehensive (loss) attributable to the non-controlling interest
|
-
|
-
|
||||||
(6,056,963
|
)
|
(19,430,579
|
)
|
|||||
Basic income (loss) per share
|
$
|
(2.83
|
)
|
$
|
(20.47
|
)
|
||
Diluted income (loss) per share
|
$
|
(2.83
|
)
|
$
|
(20.47
|
)
|
||
Basic weighted average number of shares
|
2,128,806
|
951,601
|
||||||
Diluted weighted average number of shares
|
2,128,806
|
951,601
|
Year ending December 31,
|
Amount
|
||||
2020
|
2,075,610
|
||||
2021
|
1,383,611
|
||||
2022
|
125,000
|
||||
Total
|
$
|
3,584,221
|
a. |
In August 2018, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2018-13, “Fair Value Measurement (Topic 820), Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. This ASU removed the following disclosure requirements: (1) the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; (2) the policy for timing of transfers between levels; and (3) the valuation processes for Level 3 fair value measurements. Additionally, this update added the following disclosure requirements: (1) the changes in unrealized gains and losses for the period included in other comprehensive income and loss for recurring Level 3 fair value measurements held at the end of the reporting period; (2) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic average) in lieu of the weighted average if the entity determines that other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level 3 fair value measurements. ASU No. 2018-13 will be effective for fiscal years beginning after December 15, 2019 with early adoption permitted. |
In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”. This ASU requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. ASU 2016-13 will be effective for fiscal years beginning after December 15, 2019 with early adoption permitted, and requires adoption using a modified retrospective approach, with certain exceptions. Based on the composition of the Company’s investment portfolio as of September 30, 2019, current market conditions and historical credit loss activity, the adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. Additionally, for trade receivables, due to their short duration and the credit profile of the Company’s customers, the effect of transitioning from the incurred losses model to the expected losses model is not expected to be material.
Name
|
Age
|
Position
|
Srinidhi “Dev” Devanur
|
54
|
Executive Chairman of the Board
|
Brent Kelton
|
49
|
Chief Executive Officer
|
Barry Kostiner
|
49
|
Chief Financial Officer
|
Dimitrios J. Angelis
|
50
|
Director
|
Thoranath Sukumaran
|
68
|
Director
|
Carmo Martella
|
53
|
Director
|
Committees
|
||||||||||||
Director
|
Audit
|
Compensation
|
Nominations and
Corporate
Governance
|
|||||||||
Dimitrios J. Angelis
|
X |
|
X |
|
X |
|
||||||
Thoranath Sukumaran
|
X |
|
X |
|
||||||||
Carmo Martella
|
X |
|
|
|||||||||
Srinidhi “Dev” Devanur
|
|
• |
Meeting with our management periodically to consider the adequacy of our internal controls and the objectivity of our financial reporting;
|
|
• |
Meeting with our independent registered public accounting firm and with internal financial personnel regarding the adequacy of our internal controls and the objectivity of our financial reporting;
|
|
• |
Recommending to our Board of Directors the engagement of our independent registered public accounting firm;
|
|
• |
Reviewing our quarterly and audited consolidated financial statements and reports and discussing the statements and reports with our management, including any significant adjustments, management judgments and estimates, new
accounting policies and disagreements with management; and
|
|
• |
Reviewing our financial plans and reporting recommendations to our full Board of Directors for approval and to authorize action.
|
|
• |
Base salary;
|
|
• |
Annual Incentive Bonus;
|
|
• |
Long-Term Incentives; and
|
|
• |
Retirement benefits under a 401(k) plan and generally available benefit programs.
|
Name &
Principal
|
Transition
Period
or Fiscal
Year
|
Salary
|
Bonus
|
Stock
Awards
|
Option
Awards
|
Non-Equity
Incentive
Plan
Compensation
|
Non-Qualified
Deferred
Compensation
Earnings
|
All Other
Compensation
|
Total
|
||||||||||||||||||||||||
Position
|
Ended
|
($)
|
($)
|
($)
|
($)
|
($)
|
($)
|
($)
|
($)
|
||||||||||||||||||||||||
Brent
|
12/31/2019
|
250,000
|
-
|
—
|
—
|
—
|
—
|
—
|
250,000
|
||||||||||||||||||||||||
Kelton
|
12/31/2018
|
250,000
|
100,000
|
—
|
—
|
—
|
—
|
—
|
350,000
|
||||||||||||||||||||||||
Chief
|
|||||||||||||||||||||||||||||||||
Executive
|
|||||||||||||||||||||||||||||||||
Officer
|
|||||||||||||||||||||||||||||||||
Barry
|
12/31/2019
|
200,000
|
-
|
—
|
—
|
—
|
—
|
—
|
200,000
|
||||||||||||||||||||||||
Kostiner
|
12/31/2018
|
50,000
|
10,000
|
—
|
—
|
—
|
—
|
—
|
60,000
|
||||||||||||||||||||||||
Chief
|
|||||||||||||||||||||||||||||||||
Financial
|
|||||||||||||||||||||||||||||||||
Officer
|
|||||||||||||||||||||||||||||||||
Srinidhi (Dev)
|
12/31/2019
|
250,000
|
—
|
—
|
—
|
—
|
—
|
—
|
250,000
|
||||||||||||||||||||||||
Devanur
|
12/31/2018
|
250,000
|
50,000
|
—
|
—
|
—
|
—
|
—
|
300,000
|
||||||||||||||||||||||||
Executive
|
|||||||||||||||||||||||||||||||||
Chairman
|
Plan Category
|
Number of securities to
be issued upon exercise
of outstanding options,
warrants and rights
|
Weighted-average
exercise price of
outstanding options,
warrants and rights
|
Number of securities remaining
available for future issuance under
equity compensation plans (excluding
securities reflected in column (a))
|
|||||||||
(a)
|
(b)
|
(c)
|
||||||||||
Equity compensation plans approved by security holders
|
109,938
|
$
|
29.25
|
42,114
|
||||||||
Warrants and options issued outside of our equity compensation Plan
|
—
|
|||||||||||
Total
|
109,938
|
$
|
29.25
|
42,114
|
Name
|
Fees
Earned
or Paid
in Cash
|
Stock
Awards
|
RSU & Option
Awards
|
All Other
Compensation
|
Total
|
|||||||||||||||
($)
|
($)
|
($)
|
($)
|
($)
|
||||||||||||||||
Srinidhi “Dev” Devanur
|
-
|
-
|
-
|
-
|
||||||||||||||||
Dimitrios J. Angelis
|
72,000
|
-
|
72,000
|
|||||||||||||||||
Carmo Martella
|
64,000
|
-
|
64,000
|
|||||||||||||||||
James Shad*
|
17,000
|
-
|
17,000
|
|||||||||||||||||
David Luci**
|
14,000
|
-
|
14,000
|
|||||||||||||||||
Thoranath Sukumaran
|
70,000
|
-
|
70,000
|
|||||||||||||||||
TOTAL
|
237,000
|
-
|
237,000
|
Name(1)
|
Number of Shares
Beneficially Owned
|
Percentage of
Shares
Beneficially
Owned
|
||||||
Executive Officers and Directors:
|
||||||||
Srinidhi “Dev” Devanur
|
251,055
|
7.73
|
%
|
|||||
Brent Kelton
|
43,386
|
1.34
|
%
|
|||||
Barry Kostiner
|
-
|
-
|
||||||
Dimitrios J. Angelis
|
1,642
|
*
|
||||||
Thoranath Sukumaran
|
-
|
-
|
||||||
Carmo Martella
|
-
|
-
|
||||||
All executive officers and directors as a group (6 persons)
|
296,083
|
9.12
|
%
|
* |
Less than one percent of outstanding shares.
|
(1) |
Unless otherwise indicated, the address of each person or entity is c/o AMERI Holdings, Inc., 5000 Research Court, Suite 750, Suwanee, Georgia, 30024.
|
Type of Fees
|
Year Ended
December 31,
2019
|
Year Ended
December
31,
2018
|
||||||
Audit Fees
|
$
|
85,000
|
$
|
85,000
|
||||
Audit Related Fees
|
—
|
—
|
||||||
Tax Fees
|
11,500
|
—
|
||||||
All Other Fees
|
—
|
-
|
||||||
Total
|
$
|
96,500
|
$
|
85,000
|
Exhibit
|
Description
|
Share Purchase Agreement, dated as of November 20, 2015, by and among Ameri Holdings, Inc., Bellsoft, Inc., and all of the shareholders of Bellsoft (filed as Exhibit 2.1 to Ameri Holdings, Inc.’s Current
Report on Form 8-K filed with the SEC on November 23, 2015 and incorporated herein by reference).
|
|
Agreement of Merger and Plan of Reorganization, dated as of July 22, 2016, by and among Ameri Holdings, Inc., Virtuoso Acquisition Inc., Ameri100 Virtuoso Inc., Virtuoso, L.L.C. and the sole member of
Virtuoso, L.L.C. (filed as Exhibit 2.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on July 27, 2016 and incorporated herein by reference).
|
|
Membership Interest Purchase Agreement, dated as of July 29, 2016, by and among Ameri Holdings, Inc., DC&M Partners, L.L.C., all of the members of DC&M Partners, L.L.C., Giri Devanur and Srinidhi
“Dev” Devanur (filed as Exhibit 2.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on August 1, 2016 and incorporated herein by reference).
|
|
Share Purchase Agreement, dated as of March 10, 2017, by and among Ameri Holdings, Inc., ATCG Technology Solutions, Inc., all of the stockholders of ATCG Technology Solutions, Inc., and the stockholders’
representative (filed as Exhibit 2.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on March 13, 2017 and incorporated herein by reference).
|
|
Share Purchase Agreement, dated January 10, 2020, by and between AMERI Holdings, Inc. and Ameri100, Inc.* (incorporated by reference to Exhibit 2.1 to the Company’s current report on Form 8-K, filed with the SEC on January 13, 2020)
|
|
Amalgamation Agreement, dated January 10, 2020, by and between AMERI Holdings, Inc., Jay Pharma Merger Sub, Inc., Jay Pharma Inc., Jay Pharma ExchangeCo., Inc. and Barry Kostiner.* (incorporated by reference to Exhibit 2.2 to the
Company’s current report on Form 8-K, filed with the SEC on January 13, 2020)
|
|
Amended and Restated Certificate of Incorporation of Ameri Holdings, Inc. (filed as Exhibit 3.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on June 23, 2016 and incorporated herein
by reference).
|
|
Certificate of Amendment of Certificate of Incorporation, dated November 21, 2019 (incorporated by reference to Exhibit 3.1 to the Company’s current report on Form 8-K, filed with the SEC on November 22, 2019)
|
|
Amended and Restated Certificate of Designation of Rights and Preferences of 9.00% Series A Cumulative Preferred Stock (filed as Exhibit 3.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the
SEC on August 17, 2018 and incorporated herein by reference).
|
|
Amended and Restated Bylaws of Ameri Holdings, Inc. (filed as Exhibit 3.2 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on June 23, 2016 and incorporated herein by reference).
|
|
Warrant Agent Agreement dated November 17, 2017 between Ameri Holdings, Inc. and Corporate Stock Transfer, Inc. (includes form of Warrant) (filed as Exhibit 4.1 to Ameri Holdings, Inc.’s Current Report on
Form 8-K filed with the SEC on November 17, 2017 and incorporated herein by reference).
|
|
Form of Certificate Representing Shares of Common Stock of Registrant (filed as Exhibit 4.1 to Ameri Holdings, Inc.’s Registration Statement on Form S-8 filed with the SEC on December 17, 2015 and
incorporated herein by reference).
|
Form of Common Stock Purchase Warrant issued by Ameri Holdings, Inc. to Lone Star Value Investors, LP, dated May 26, 2015 (filed as Exhibit 4.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on June 1, 2015 and
incorporated herein by reference).
|
|
Common Stock Purchase Warrant, dated May 12, 2016, issued by Ameri Holdings, Inc. to Lone Star Value Investors, LP, dated May 12, 2016 (filed as Exhibit 4.3 to Ameri Holdings, Inc.’s Quarterly Report on Form 10-Q filed with the SEC on
May 16, 2016 and incorporated herein by reference).
|
|
Description of Securities
|
|
Form of 8% Convertible Unsecured Promissory Note due March 2020 (filed as Exhibit 10.2 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on March 8, 2017 and incorporated herein by reference).
|
|
Form of 6% Unsecured Promissory Note (filed as Exhibit 10.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on March 13, 2017 and incorporated herein by reference).
|
|
Form of Warrant issued in July 2018 Financing (filed as Exhibit 4.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on July 30, 2018 and incorporated herein by reference).
|
|
Form of Placement Agent Warrant issued in July 2018 Financing (filed as Exhibit 4.2 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on July 30, 2018 and incorporated herein by reference).
|
|
Warrant Agent Agreement dated August 16, 2018 between Ameri Holdings, Inc. and Corporate Stock Transfer, Inc. (includes form of Warrant) (filed as Exhibit 4.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on
August 17, 2018 and incorporated herein by reference).
|
|
Securities Purchase Agreement, dated as of May 26, 2015, by and between Ameri Holdings, Inc. and Lone Star Value Investors, LP. (filed as Exhibit 10.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on June 1,
2015 and incorporated herein by reference).
|
|
Form of Director Indemnification Agreement. (filed as Exhibit 10.6 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on June 1, 2015 and incorporated herein by reference).
|
|
Form of Option Grant Letter. (filed as Exhibit 10.7 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on June 1, 2015 and incorporated herein by reference).
|
|
2015 Equity Incentive Award Plan. (filed as Exhibit 10.8 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on June 1, 2015 and incorporated herein by reference).
|
|
Form of Restricted Stock Unit Agreement (filed as Exhibit 10.1 to Ameri Holdings, Inc.’s Quarterly Report on Form 10-Q filed with the SEC on November 23, 2015 and incorporated herein by reference).
|
|
Exchange Agreement, dated as of December 30, 2016, between Ameri Holdings, Inc. and Lone Star Value Investors, LP (filed as Exhibit 10.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on January 4, 2017 and
incorporated herein by reference).
|
|
Amendment to 6% Unsecured Promissory Note and Waiver Agreement, dated February 28, 2018, by and between Ameri Holdings, Inc. and Moneta Ventures Fund I, L.P. (filed as Exhibit 10.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K
filed with the SEC on March 2, 2018 and incorporated herein by reference).
|
|
Amendment Agreement, dated as of June 22, 2018, by and between Ameri Holdings, Inc. and Lone Star Value Investors, LP. (filed as Exhibit 10.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on June 26, 2018 and
incorporated herein by reference).
|
|
First Amendment to the Ameri Holdings, Inc. 2015 Equity Incentive Award Plan. (filed as Exhibit 10.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on August 17, 2018 and incorporated herein by reference).
|
Employment Letter, dated October 17, 2018, between Ameri and Partners Inc and Barry Kostiner (filed as Exhibit 10.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on October 17, 2018 and incorporated herein by
reference).
|
|
Employment Agreement between Srinidhi “Dev” Devanur and the Company, effective December 11, 2018 (filed as Exhibit 10.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on December 14, 2018 and incorporated herein
by reference).
|
|
Loan and Security Agreement, dated January 23, 2019, by and between (i) Ameri100 Arizona LLC, (ii) Ameri100 Georgia, Inc., (iii) Ameri100 California, Inc. and (iv) Ameri and Partners, Inc. and North Mill Capital LLC (filed as Exhibit
10.1 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on January 25, 2019 and incorporated herein by reference).
|
|
Revolving Credit Master Promissory Note, dated January 23, 2019 (filed as Exhibit 10.2 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on January 25, 2019 and incorporated herein by reference).
|
|
Corporate Guaranty, dated January 23, 2019, by Ameri Holdings, Inc. in favor of North Mill Capital LLC (filed as Exhibit 10.3 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on January 25, 2019 and incorporated
herein by reference).
|
|
Security Agreement, dated January 23, 2019, by and between Ameri Holdings, Inc. and North Mill Capital LLC (filed as Exhibit 10.4 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on January 25, 2019 and
incorporated herein by reference).
|
|
Form of Guarantor Indemnification Agreement (filed as Exhibit 10.5 to Ameri Holdings, Inc.’s Current Report on Form 8-K filed with the SEC on January 25, 2019 and incorporated herein by reference).
|
|
Form of Exchange Agreement (incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K, filed with the SEC on September 20, 2019)
|
|
Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K, filed with the SEC on November 25, 2019)
|
|
Form of Convertible Debenture (incorporated by reference to Exhibit 10.2 to the Company’s current report on Form 8-K, filed with the SEC on November 25, 2019)
|
|
Form of Exchange Agreement, by and among AMERI Holdings, Inc., Ameri100, Inc. and each Converted Debt Holder* (incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K, filed with the SEC on January 13, 2020)
|
|
Note Purchase and Security Agreement (incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K, filed with the SEC on March 4, 2020)
|
|
Secured Promissory Note (incorporated by reference to Exhibit 10.2 to the Company’s current report on Form 8-K, filed with the SEC on March 4, 2020)
|
|
List of Subsidiaries.
|
|
Consent of Ram Associates, CPA.
|
|
Section 302 Certification of Principal Executive Officer
|
|
Section 302 Certification of Principal Financial and Accounting Officer
|
|
Section 906 Certification of Principal Executive Officer
|
|
Section 906 Certification of Principal Financial and Accounting Officer
|
|
101*
|
The following materials from Ameri Holdings, Inc.’s Annual Report on Form 10-K for the twelve months ended December 31, 2017 are formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the
Consolidated Statements of Operations, (iii) the Consolidated Statement of Stockholders’ Equity (Deficit), (iv) the Consolidated Statements of Cash Flow, and (iv) Notes to the Consolidated Financial Statements.
|
*
|
Filed herewith.
|
**
|
In accordance with Item 601of Regulation S-K, this Exhibit is hereby furnished to the SEC as an accompanying document and is not deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933.
|
PAGE
|
|
CONSOLIDATED FINANCIAL STATEMENTS OF AMERI HOLDINGS, INC. AS OF DECEMBER 31, 2019 AND 2018 AND FOR THE YEARS THEN ENDED
|
|
Report of Independent Registered Public Accounting Firm
|
F-2
|
Consolidated Balance Sheets
|
F-3
|
Consolidated Statements of Operations and Comprehensive Income (Loss)
|
F-4
|
Consolidated Statement of Changes in Stockholders’ Equity From December 31, 2017 to December 31, 2019
|
F-5
|
Consolidated Statements of Cash Flows for the Years Ended December 31, 2019 and December 31, 2018
|
F-6
|
Notes to Consolidated Financial Statements
|
F-7
|
December 31,
2019
|
December 31,
2018
|
|||||||
Assets
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
431,400
|
$
|
1,371,331
|
||||
Accounts receivable
|
6,384,148
|
7,871,422
|
||||||
Other current assets
|
783,606
|
818,600
|
||||||
Total current assets
|
7,599,154
|
10,061,353
|
||||||
Other assets:
|
||||||||
Property and equipment, net
|
83,128
|
58,892
|
||||||
Intangible assets, net
|
3,584,221
|
5,778,036
|
||||||
Goodwill
|
13,729,770
|
13,729,770
|
||||||
Deferred income tax assets, net
|
8,879
|
9,399
|
||||||
Total other assets
|
17,405,998
|
19,576,097
|
||||||
Total assets
|
$
|
25,005,152
|
$
|
29,637,450
|
||||
Liabilities
|
||||||||
Current liabilities:
|
||||||||
Line of credit
|
$
|
2,881,061
|
$
|
3,950,681
|
||||
Accounts payable
|
4,696,352
|
4,377,794
|
||||||
Other accrued expenses
|
1,989,894
|
1,697,636
|
||||||
Current portion - long-term notes
|
-
|
6,450
|
||||||
Convertible notes
|
1,000,000
|
1,250,000
|
||||||
Debentures
|
1,000,000
|
-
|
||||||
Consideration payable – cash
|
2,496,000
|
2,696,000
|
||||||
Consideration payable – equity
|
-
|
605,223
|
||||||
Dividend payable – Preferred stock
|
320,298
|
105,181
|
||||||
Total current liabilities
|
14,383,605
|
14,688,965
|
||||||
Long-term liabilities:
|
||||||||
Warrant liability
|
-
|
4,189,388
|
||||||
Total long-term liabilities
|
-
|
4,189,388
|
||||||
Total liabilities
|
14,383,605
|
18,878,353
|
||||||
Stockholders’ equity:
|
||||||||
Preferred stock, $0.01 par value; 1,000,000 authorized, 424,938 and 420,720 issued and outstanding as of December 31, 2019 and December 31, 2018, respectively
|
4,249
|
4,207
|
||||||
Common stock, $0.01 par value; 100,000,000 shares authorized, 2,522,095 and 1,693,165 issued and outstanding as of December 31, 2019 and December 31, 2018,
respectively
|
25,221
|
16,932
|
||||||
Additional paid-in capital
|
51,040,296
|
45,129,214
|
||||||
Accumulated deficit
|
(40,508,231
|
)
|
(34,478,253
|
)
|
||||
Accumulated other comprehensive income (loss)
|
60,012
|
86,997
|
||||||
Total stockholders’ equity
|
10,621,547
|
10,759,097
|
||||||
Total liabilities and stockholders’ equity
|
$
|
25,005,152
|
$
|
29,637,450
|
|
Twelve Months
Ended December 31,
|
|||||||
|
2019
|
2018
|
||||||
|
||||||||
Net revenue
|
$
|
39,914,675
|
$ |
42,998,280
|
||||
Cost of revenue
|
31,763,955
|
34,014,776
|
||||||
Gross profit
|
8,150,720
|
8,983,504
|
||||||
|
||||||||
Operating expenses:
|
||||||||
Selling, general and administration
|
12,210,317
|
10,794,822
|
||||||
Depreciation and amortization
|
2,265,297
|
2,903,662
|
||||||
Acquisition related expenses
|
-
|
333,237
|
||||||
Changes in estimate for consideration payable
|
-
|
(6,940,310
|
)
|
|||||
Impairment charges on goodwill and intangible assets
|
-
|
9,038,553
|
||||||
Operating expenses
|
14,475,614
|
16,129,964
|
||||||
Operating Income (loss):
|
(6,324,894
|
)
|
(7,146,460
|
)
|
||||
|
||||||||
Interest expense
|
(691,138
|
)
|
(729,896
|
)
|
||||
Other income
|
4,540
|
88,161
|
||||||
Change in fair value of warrant liability
|
1,796,174
|
(2,760,819
|
)
|
|||||
Total other income /(expenses)
|
1,109,576
|
(3,402,554
|
)
|
|||||
Income (loss) before income taxes
|
(5,215,318
|
)
|
(10,549,014
|
)
|
||||
Income tax benefit
|
(388,657
|
)
|
(6,348,502
|
)
|
||||
Net Income (loss)
|
(5,603,975
|
)
|
(16,897,516
|
)
|
||||
Dividend on preferred stock
|
(426,003
|
)
|
(2,583,185
|
)
|
||||
Net (loss) attributable to common stock holders
|
(6,029,978
|
)
|
(19,480,701
|
)
|
||||
Other comprehensive income/ (loss), net of tax:
|
||||||||
Foreign exchange translation adjustment
|
(26,985
|
)
|
50,122
|
|||||
Total comprehensive income (loss)
|
$
|
(6,056,963
|
)
|
(19,430,579
|
)
|
|||
Comprehensive (loss) attributable to the Company
|
(6,056,963
|
)
|
(19,430,579
|
)
|
||||
Comprehensive (loss) attributable to the non-controlling interest
|
-
|
-
|
||||||
(6,056,963
|
)
|
(19,430,579
|
)
|
|||||
Basic income (loss) per share
|
$
|
(2.83
|
)
|
$
|
(20.47
|
)
|
||
Diluted income (loss) per share
|
$
|
(2.83
|
)
|
$
|
(20.47
|
)
|
||
|
||||||||
Basic weighted average number of shares
|
2,128,806
|
951,601
|
||||||
Diluted weighted average number of shares
|
2,128,806
|
951,601
|
Common Stock
|
Preferred Stock
|
|||||||||||||||||||||||||||||||
Shares
|
Par
Value at
$0.01
|
Shares
|
Par Value
at $0.01
|
Additional
paid-in
capital
|
Foreign
Currency
Translation
Reserve
|
Retained
earnings
|
Total
stockholders'
equity
|
|||||||||||||||||||||||||
Balance at Dec 31, 2017
|
726,509
|
$
|
7,265
|
405,395
|
$
|
4,054
|
$
|
34,397,541
|
$
|
36,877
|
$
|
(14,997,552
|
)
|
$
|
19,448,185
|
|||||||||||||||||
Net Loss for the period
|
(19,480,701
|
)
|
(19,480,701
|
)
|
||||||||||||||||||||||||||||
Other comprehensive income (loss)
|
50,120
|
50,120
|
||||||||||||||||||||||||||||||
Warrants conversion to shares
|
781,486
|
7,815
|
698,453
|
706,268
|
||||||||||||||||||||||||||||
Shares Issued as consideration for acquisition of Subsidiary (ATCG)
|
11,334
|
113
|
605,110
|
605,223
|
||||||||||||||||||||||||||||
Shares Issued towards earnout
|
15,561
|
156
|
642,694
|
642,850
|
||||||||||||||||||||||||||||
Stock, Option, RSU and Warrant Expense
|
-
|
1,239,989
|
1,239,989
|
|||||||||||||||||||||||||||||
Compensation to Directors
|
3,875
|
39
|
(39
|
)
|
-
|
|||||||||||||||||||||||||||
Conversion of Options
|
22,400
|
224
|
806,175
|
806,399
|
||||||||||||||||||||||||||||
Shares issued - Private Placement
|
130,000
|
1,300
|
4,249,960
|
4,251,260
|
||||||||||||||||||||||||||||
Isuue of Preference shares for Q1 and Q2 dividend
|
-
|
15,325
|
153
|
766,055
|
766,208
|
|||||||||||||||||||||||||||
Shares Issued on seperation
|
2,000
|
20
|
11,480
|
11,500
|
||||||||||||||||||||||||||||
LSV - Preferred Dividend
|
-
|
1,711,796
|
1,711,796
|
|||||||||||||||||||||||||||||
-
|
||||||||||||||||||||||||||||||||
Balance at December 31, 2018
|
1,693,165
|
$
|
16,932
|
420,720
|
$
|
4,207
|
$
|
45,129,214
|
$
|
86,997
|
$
|
(34,478,253
|
)
|
$
|
10,759,097
|
|||||||||||||||||
Balance at Dec 31, 2018
|
1,693,165
|
$
|
16,932
|
420,720
|
$
|
4,207
|
$
|
45,129,214
|
$
|
86,997
|
$
|
(34,478,253
|
)
|
$
|
10,759,097
|
|||||||||||||||||
Net Loss for the period
|
(6,029,978
|
)
|
(6,029,978
|
)
|
||||||||||||||||||||||||||||
Other comprehensive income (loss)
|
(26,985
|
)
|
(26,985
|
)
|
||||||||||||||||||||||||||||
Shares Issued towards earnouts
|
131,570
|
1,316
|
603,909
|
605,225
|
||||||||||||||||||||||||||||
Exercise of Warrants (PIPE series A&B)
|
688,097
|
6,881
|
4,509,927
|
4,516,808
|
||||||||||||||||||||||||||||
Stock Compensation expenses
|
586,495
|
586,495
|
||||||||||||||||||||||||||||||
Preferred stock issued
|
4,218
|
42
|
210,844
|
210,886
|
||||||||||||||||||||||||||||
Shares issued for Fraction shares on reverse split
|
9,263
|
93
|
(93
|
)
|
-
|
|||||||||||||||||||||||||||
Balance at December 31, 2019
|
2,522,095
|
$
|
25,221
|
424,938
|
$
|
4,249
|
$
|
51,040,296
|
$
|
60,012
|
$
|
(40,508,231
|
)
|
$
|
10,621,547
|
December, 31
|
||||||||
2019
|
2018
|
|||||||
Cash flow from operating activities
|
||||||||
Net Income (loss)
|
(6,029,978
|
)
|
(19,480,701
|
)
|
||||
Adjustment to reconcile comprehensive income/(loss) to net cash used in operating activities
|
||||||||
Depreciation and amortization
|
2,265,297
|
2,903,662
|
||||||
Impairment on goodwill and Intangible assets
|
-
|
9038553
|
||||||
Provision for Preference dividend
|
426,003
|
2,583,184
|
||||||
Changes in fair value of warrants
|
(1,796,174
|
)
|
2,760,819
|
|||||
Changes in estimate of contingent consideration
|
-
|
(6,940,310
|
)
|
|||||
Stock, option, restricted stock unit and warrant expense
|
586,495
|
1,251,489
|
||||||
Foreign exchange translation adjustment
|
(26,985
|
)
|
-
|
|||||
Provision for Income taxes ( net off deferred income taxes)
|
388,657
|
6,348,502
|
||||||
Loss on sale of fixed assets
|
(11,386
|
)
|
(2,139
|
)
|
||||
Changes in assets and liabilities:
|
||||||||
Increase (decrease) in:
|
||||||||
Accounts receivable
|
1,487,274
|
967,031
|
||||||
Other current assets
|
34,994
|
105,666
|
||||||
Increase (decrease) in:
|
||||||||
Accounts payable and accrued expenses
|
222,679
|
(2,101,251
|
)
|
|||||
Net cash provided by (used in) operating activities
|
(2,453,123
|
)
|
(2,565,495
|
)
|
||||
Cash flow from investing activities
|
||||||||
Purchase of fixed assets
|
(84,331
|
)
|
6,421
|
|||||
Acquisition consideration
|
(200,000
|
)
|
(3,645,667
|
)
|
||||
Investments
|
-
|
|||||||
Net cash used in investing activities
|
(284,331
|
)
|
(3,639,246
|
)
|
||||
Cash flow from financing activities
|
||||||||
Proceeds from bank loan and convertible notes, net
|
(1,326,070
|
)
|
(1,976,299
|
)
|
||||
Proceeds from Issue of debentures
|
1,000,000
|
-
|
||||||
Contingent consideration for acquisitions
|
-
|
(1,657,667
|
)
|
|||||
Proceeds from issuance of common shares, net
|
2,123,594
|
6,327,954
|
||||||
Net cash provided by financing activities
|
1,797,524
|
2,693,988
|
||||||
Net increase (decrease) in cash and cash equivalents
|
(939,931
|
)
|
(3,510,753
|
)
|
||||
Cash and cash equivalents as at beginning of the period
|
1,371,331
|
4,882,084
|
||||||
Cash at the end of the period
|
431,400
|
1,371,331
|
SUPPLEMENTAL DISCLOSURES:
|
||||||||
Cash paid during the period for:
|
||||||||
Interest
|
$
|
480,404
|
$
|
571,628
|
||||
Taxes
|
$
|
-
|
|
$
|
-
|
NOTE 2. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
|
In August 2018, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2018-13, “Fair Value Measurement (Topic 820), Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. This ASU removed the following disclosure requirements: (1) the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; (2) the policy for timing of transfers between levels; and (3) the valuation processes for Level 3 fair value measurements. Additionally, this update added the following disclosure requirements: (1) the changes in unrealized gains and losses for the period included in other comprehensive income and loss for recurring Level 3 fair value measurements held at the end of the reporting period; (2) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic average) in lieu of the weighted average if the entity determines that other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level 3 fair value measurements. ASU No. 2018-13 will be effective for fiscal years beginning after December 15, 2019 with early adoption permitted.
In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”. This ASU requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. ASU 2016-13 will be effective for fiscal years beginning after December 15, 2019 with early adoption permitted, and requires adoption using a modified retrospective approach, with certain exceptions. Based on the composition of the Company’s investment portfolio as of September 30, 2019, current market conditions and historical credit loss activity, the adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. Additionally, for trade receivables, due to their short duration and the credit profile of the Company’s customers, the effect of transitioning from the incurred losses model to the expected losses model is not expected to be material.
NOTE 3. |
EQUITY TRANSACTIONS:
|
(a)
|
the payment of the March 31, 2018 dividend payment in-kind in shares of Series A Preferred;
|
|
(b) |
elimination of any prior default in respect of non-payment of accrued dividends through the filing effective date of the Amendment (the “Effective Date”);
|
|
(c) |
payment in-kind in shares of Series A Preferred of dividends for all dividend periods from April 1, 2018 through March 31, 2020 at a rate of 2% per annum of the liquidation preference (the “Adjusted Rate”); and
|
|
(d) |
commencing April 1, 2020, we will pay cash dividends per share at a rate per annum equal to the Adjusted Rate multiplied by the liquidation preference; provided, however, dividends for periods ending after April 1, 2020 may be
paid at the election of our Board of Directors in-kind through the issuance of additional shares of Series A Preferred for up to four dividend periods in any consecutive 36-month period, determined on a rolling basis.
|
NOTE 4. |
BUSINESS COMBINATIONS:
|
|
(a) |
A cash payment in the amount of $340,000 which was due within 90 days of closing and was paid on September 22, 2016;
|
|
(b) |
Warrants for the purchase of 2,040 shares of our common stock (valued at approximately $250,000 based on the $162.75 closing price of our common stock on the closing date of the acquisition), with such warrants exercisable for
two years. The former shareholders of Bigtech exercised such warrants in full and were issued shares of common stock as of July 5, 2018; and
|
|
(c) |
$255,000 payable in cash earn-outs to the sellers of Bigtech, if Bigtech achieved certain pre-determined revenue and EBITDA targets in 2017 and 2018. On October 4, 2018, we issued an aggregate of 2,903 shares of common stock to
the former shareholders of Bigtech in satisfaction of an earn-out owed to them. As of October 4, 2018, we had resolved all remaining payments under the Bigtech purchase agreement and we have no
further payment obligations pursuant thereto.
|
|
(a) |
A cash payment in the amount of $3,000,000 at closing;
|
|
(b) |
64,000 shares of our common stock (valued at approximately $10.4 million based on the $162.75 closing price of our common stock on the closing date of the acquisition), which were to be issued on July 29, 2018 or upon a change of
control of our company (whichever occurred earlier). At the election of the former members of Ameri Arizona, in lieu of receiving shares of our common stock, each former member was entitled to receive a cash payment of $60 per
share; and
|
|
(c) |
Earn-out payments of $1,500,000 payable in cash each year to be paid, if earned, through the achievement of annual revenue and gross margin targets in 2017 and 2018.
|
|
(a) |
23,077 shares of our common stock, valued at approximately $3.8 million based on the closing price of our common stock on the closing date of the acquisition;
|
|
(b) |
Unsecured promissory notes issued to certain of Ameri California’s selling stockholders for the aggregate amount of $3,750,000 (which notes bear interest at a rate of 6% per annum and mature on June
30, 2018);
|
|
(c) |
Earn-out payments in shares of our common stock (up to an aggregate value of $1.2 million worth of shares) to be paid, if earned, in each of 2018 and 2019 based on certain revenue and earnings before
interest taxes, depreciation and amortization (“EBITDA”) targets as specified in the purchase agreement. We have determined that the earn-out targets for each year have been fully achieved, and 11,334 shares of common stock were
issued in 2018 in respect of the 2017 earn-out period and $605,000 worth of common stock was issued in January 2019 in respect of the 2018 earn-out period; and
|
|
(d) |
An additional cash payment of $0.06 million for cash that was left in Ameri California at closing.
|
Allocation of purchase price in millions of U.S. dollars
|
||||||||||||||||||||
Asset Component
|
Ameri Georgia
|
Bigtech
|
Virtuoso
|
Ameri Arizona
|
Ameri
California
|
|||||||||||||||
Intangible Assets
|
1.8
|
0.6
|
0.9
|
5.4
|
3.8
|
|||||||||||||||
Goodwill
|
3.5
|
0.3
|
0.9
|
10.4
|
5.0
|
|||||||||||||||
Working Capital
|
||||||||||||||||||||
Current Assets
|
||||||||||||||||||||
Cash
|
1.4
|
-
|
-
|
-
|
-
|
|||||||||||||||
Accounts Receivable
|
5.6
|
-
|
-
|
-
|
-
|
|||||||||||||||
Other Assets
|
0.2
|
-
|
-
|
-
|
-
|
|||||||||||||||
7.3
|
-
|
-
|
-
|
-
|
||||||||||||||||
Current Liabilities
|
||||||||||||||||||||
Accounts Payable
|
1.3
|
-
|
-
|
-
|
-
|
|||||||||||||||
Accrued Expenses & Other Current Liabilities
|
1.3
|
-
|
-
|
-
|
-
|
|||||||||||||||
2.7
|
-
|
-
|
-
|
-
|
||||||||||||||||
Net Working Capital Acquired
|
4.6
|
-
|
-
|
-
|
-
|
|||||||||||||||
Total Purchase Price
|
9.9
|
0.9
|
1.8
|
15.8
|
8.8
|
NOTE 5. |
INTANGIBLE ASSETS:
|
2019
|
2018
|
|||||||||||||||||||||||
Gross Carrying
Amount
|
Accumulated
Amortization
and
Impairment
|
Net
Carrying
Amount
|
Gross Carrying
Amount
|
Accumulated
Amortization
|
Net
Carrying
Amount
|
|||||||||||||||||||
Customer lists
|
$
|
13,563,414
|
9,986,414
|
3,577,000
|
13,563,414
|
7,793,414
|
5,770,000
|
|||||||||||||||||
Software
|
$
|
425,064
|
417,843
|
7,221
|
425,064
|
417,028
|
8,036
|
|||||||||||||||||
Total intangible assets:
|
$
|
13,988,478
|
10,404,257
|
3,584,221
|
13,988,478
|
8,210,442
|
5,778,036
|
Year ending December 31,
|
Amount
|
|||
2020
|
2,075,610
|
|||
2021
|
1,383,611
|
|||
2022
|
125,000
|
|||
Total
|
$
|
3,584,221
|
NOTE 6. |
GOODWILL:
|
December 31,
2019
|
December 31,
2018
|
|||||||
Ameri Arizona
|
$
|
5,450,000
|
$
|
5,450,000
|
||||
Ameri Georgia
|
3,470,522
|
3,470,522
|
||||||
Ameri California
|
4,809,248
|
4,809,248
|
||||||
Total
|
$
|
13,729,770
|
$
|
13,729,770
|
NOTE 7. |
SHARE-BASED COMPENSATION:
|
NOTE 8. |
EQUITY COMPENSATION PLANS:
|
Options
|
RSUs
|
Shares of Stock
|
||||||||||||||||||||||
No. of
Options
|
Weighted
Average
Price
|
No of
RSUs
|
No of
Shares
|
Weighted
Average
Price
|
Total
|
|||||||||||||||||||
Equity compensation plan total shares
|
-
|
-
|
80,000
|
|||||||||||||||||||||
Granted
|
6,000
|
66.75
|
3,328
|
0
|
0
|
9,328
|
||||||||||||||||||
Cancelled/expired
|
0
|
0
|
0
|
0
|
0
|
0
|
||||||||||||||||||
Balance outstanding as at December 31, 2015
|
6,000
|
66.75
|
3,328
|
0
|
0
|
0
|
||||||||||||||||||
Balance available under the plan as at December 31, 2015
|
0
|
0
|
0
|
0
|
0
|
70,672
|
||||||||||||||||||
Granted
|
39,028
|
169.75
|
20,307
|
0
|
0
|
59,335
|
||||||||||||||||||
Cancelled/expired
|
6,400
|
135.25
|
0
|
0
|
0
|
6,400
|
||||||||||||||||||
Balance outstanding as at December 31, 2016
|
38,628
|
159.5
|
23,635
|
0
|
0
|
0
|
||||||||||||||||||
Balance available under the plan as at December 31, 2016
|
0
|
0
|
0
|
0
|
0
|
17,737
|
||||||||||||||||||
Granted
|
11,400
|
140.5
|
3,045
|
7944
|
64.5
|
22,389
|
||||||||||||||||||
Cancelled/Expired
|
3,616
|
163.5
|
7,633
|
0
|
0
|
11,249
|
||||||||||||||||||
Balance outstanding as at December 31, 2017
|
46,412
|
152.5
|
19,047
|
7944
|
64.5
|
0
|
||||||||||||||||||
Balance available under the plan as at December 31, 2017
|
0
|
0
|
0
|
0
|
0
|
6,597
|
||||||||||||||||||
New pool added
|
0
|
0
|
0
|
0
|
0
|
80,000
|
||||||||||||||||||
Granted
|
74,480
|
36.75
|
5,675
|
0
|
0
|
80,155
|
||||||||||||||||||
Cancelled/expired
|
34,072
|
150
|
1,599
|
0
|
0
|
35,671
|
||||||||||||||||||
Balance available under the plan as at December 31, 2018
|
0
|
0
|
0
|
0
|
0
|
42,114
|
||||||||||||||||||
New pool added
|
0
|
0
|
0
|
0
|
0
|
0
|
||||||||||||||||||
Granted
|
0
|
0
|
0
|
0
|
0
|
0
|
||||||||||||||||||
Cancelled/expired
|
32,908
|
0
|
0
|
0
|
0
|
32,908
|
||||||||||||||||||
Balance available under the plan as at December 31, 2019
|
0
|
0
|
0
|
0
|
0
|
75,022
|
•
|
Expected term of 3.25 years.
|
•
|
Expected volatility of 111.8%.
|
•
|
Risk-free interest rate of 0.57%.
|
•
|
Expected dividend yield of 0%.
|
NOTE 9.
|
WARRANTS:
|
Number of
Shares
|
Weighted Average,
Exercise Price
|
Weighted Average,
Remaining term
|
||||||||||
Warrants Outstanding at December 31, 2014
|
||||||||||||
Granted
|
111,111
|
45
|
4.41
|
|||||||||
Exercised
|
-
|
-
|
-
|
|||||||||
Warrants Outstanding at December 31, 2015
|
111,111
|
45.00
|
4.41
|
|||||||||
Granted
|
40,000
|
150.00
|
-
|
|||||||||
Exercised
|
4,444
|
45.00
|
-
|
|||||||||
Warrants Outstanding at December 31, 2016
|
106,667
|
45.00
|
3.9
|
|||||||||
Granted
|
59,000
|
103.13
|
||||||||||
Exercised
|
66,667
|
45.00
|
||||||||||
Warrants Outstanding at December 31, 2017
|
99,000
|
122.00
|
3.14
|
|||||||||
Granted
|
1,682,110
|
4.50
|
||||||||||
Exercised
|
779,446
|
0.75
|
||||||||||
Warrants Outstanding at December 31, 2018
|
1,001,664
|
18.75
|
3.46
|
|||||||||
Granted
|
-
|
-
|
||||||||||
Exercised
|
902,786
|
0.25
|
||||||||||
Warrants Outstanding at December 31, 2019
|
98,878
|
117.75
|
1.26
|
NOTE 10. |
EARNINGS / (LOSS) PER SHARE:
|
For the Twelve Months Ended
|
||||||||
December 31,
2019
|
December 31,
2018
|
|||||||
Numerator for basic and diluted income (loss) per share:
|
||||||||
Net income (loss) attributable to common stockholders
|
$
|
(6,029,978
|
)
|
(19,480,701
|
)
|
|||
Numerator for diluted income (loss) per share:
|
||||||||
Net income (loss) attributable to common stockholders - as reported
|
$
|
(6,029,978
|
)
|
(19,480,701
|
)
|
|||
Interest expense on 2017 Notes, net of taxes
|
-
|
-
|
||||||
Net income (loss) attributable to common stockholders - after assumed conversions of dilutive shares
|
$
|
(6,029,978
|
)
|
(19,480,701
|
)
|
|||
Denominator for weighted average common shares outstanding:
|
||||||||
Basic shares
|
2,128,806
|
951,601
|
||||||
Dilutive effect of Equity Awards
|
-
|
|||||||
Dilutive effect of 2017 Notes
|
-
|
-
|
||||||
Diluted shares
|
2,128,806
|
951,601
|
||||||
|
||||||||
Income (loss) per share – basic:
|
$
|
(2.83
|
)
|
(20.47
|
)
|
|||
Income (loss) per share – diluted:
|
$
|
(2.83
|
)
|
(20.47
|
)
|
NOTE 11. |
DEBT:
|
2019
|
2018
|
|||||||
Notes outstanding under revolving credit facility
|
$
|
2,881,061
|
$
|
3,950,681
|
||||
Convertible note
|
1,000,000
|
1,250,000
|
||||||
Debentures
|
1,000,000
|
-
|
||||||
Term loan - current maturities
|
-
|
6,450
|
||||||
Total short-term debt
|
$
|
4,881,061
|
$
|
5,207,131
|
NOTE 12. |
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES:
|
December 31,2019
|
December 31,2018
|
||||||||
1
|
Salaries, commissions and other benefits payable
|
737,787
|
950,257
|
||||||
2
|
Professional & legal fees payable
|
148,743
|
109,246
|
||||||
3
|
Interest payable
|
219,204
|
172,466
|
||||||
4
|
Taxes Payable
|
648,460
|
182,298
|
||||||
5
|
Other liabilities
|
235,700
|
283,369
|
||||||
1,989,894
|
1,697,636
|
NOTE 13. |
EMPLOYEE BENEFIT PLAN:
|
NOTE 14. |
INCOME TAXES:
|
2019
|
2018
|
|||||||
Current:
|
||||||||
Federal and state
|
$
|
97,465
|
$
|
125,356
|
||||
Foreign
|
278,004
|
109,917
|
||||||
Total current provision/(benefit)
|
375,469
|
235,273
|
||||||
Deferred:
|
||||||||
Federal and state
|
-
|
-
|
||||||
Foreign
|
13,188
|
24,478
|
||||||
Valuation allowance
|
-
|
6,088,751
|
||||||
Total deferred expense (benefit)
|
13,188
|
6,113,229
|
||||||
Total income tax expense (benefit)
|
$
|
388,657
|
$
|
6,348,502
|
NOTE 15. |
COMMITMENTS AND CONTINGENCIES:
|
Year ending December 31
|
Total
|
|||
2020
|
265,264
|
|||
2021
|
156,868
|
|||
2022
|
113,565
|
|||
2023
|
116,969
|
|||
2024
|
120,476
|
|||
2025
|
124,091
|
|||
2026
|
127,814
|
|||
2027
|
64,692
|
|||
Total
|
1,089,739
|
NOTE 16. |
FAIR VALUE MEASUREMENT:
|
|
• |
Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;
|
|
• |
Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration,
for substantially the full term of the financial instrument; and
|
|
• |
Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.
|
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
Cash equivalents:
|
$
|
-
|
$
|
-
|
$ |
$
|
-
|
|||||||||
Warrant liability
|
-
|
-
|
||||||||||||||
Contingent consideration
|
-
|
-
|
-
|
-
|
||||||||||||
Total
|
-
|
-
|
$
|
-
|
$
|
-
|
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
Cash equivalents:
|
$
|
-
|
$
|
-
|
$ |
$
|
-
|
|||||||||
Warrant liability
|
4,189,388
|
4,189,388
|
||||||||||||||
Contingent consideration
|
-
|
-
|
605,223
|
605,223
|
||||||||||||
Total
|
-
|
-
|
$
|
4,794,611
|
$
|
4,794,611
|
Closing balance December 31st 2018
|
4,794,611
|
|||
Additions during the period
|
$
|
-
|
||
Paid/settlements
|
(4,794,611
|
)
|
||
Total gains recognized in Statement of Operations
|
-
|
|||
Closing balance December 31st 2019
|
$
|
-
|
NOTE 17. |
SUBSEQUENT EVENTS:
|
|
• |
the accuracy of the other party’s representations and warranties and the performance, in all material respects, by the other party of its obligations under the Agreement;
|
|
• |
the Company obtaining the approval of the Spin-Off from its stockholders at the Company Special Meeting (as defined below);
|
|
• |
the consummation of the Reorganization; and
|
|
• |
the consummation of the Amalgamation (as defined below).
|
|
• |
an undertaking to prepare and file with the SEC, as promptly as reasonably practicable following the date of the Amalgamation Agreement, (a) a proxy statement (the “Proxy Statement”) asking its shareholders to vote on and approve any and all required proposals (the “Company Shareholder Proposals”) necessary to
consummate the transactions contemplated by the Amalgamation and the Spin-Off at a special meeting (the “Company Special Meeting”) and (b) a Registration Statement or Statements on Forms S-4, S-1, S-3 or S-8, as
applicable (including all amendments thereto, and collectively, the “Registration Statement”) registering all shares of Resulting Issuer Capital Stock (as defined in the Amalgamation Agreement) issued in connection with the
Amalgamation;
|
|
• |
an undertaking to prepare and submit a NASDAQ Listing Application and use commercially reasonable efforts to cause such NASDAQ Listing Application to be conditionally approved prior to the Effective Time; and
|
|
• |
an undertaking to consummate an equity financing that eliminates all of the outstanding liabilities of the Company prior to the Effective Time (the “Company Financing”).
|
|
• |
the accuracy of the other parties representations and warranties and the performance, in all material respects, by the other parties of its obligations under the Amalgamation Agreement;
|
|
• |
the approval of the Company Shareholder Proposals at the Company Special Meeting;
|
|
• |
the consummation of the Spin-Off;
|
|
• |
the consummation of the Company Financing;
|
|
• |
the approval of the Jay Pharma stockholders;
|
|
• |
the entering into of certain ancillary agreements by and between the Company and ExchangeCo;
|
|
• |
the approval of the NASDAQ Listing Application; and
|
|
• |
the Company shall have effectuated the Stock Split (as defined in the Amalgamation Agreement), if necessary.
|
AMERI Holdings, Inc.
|
||
By:
|
/s/ Brent Kelton
|
|
Brent Kelton
|
||
Chief Executive Officer (Principal Executive Officer)
|
||
By:
|
/s/ Barry Kostiner
|
|
Barry Kostiner
|
||
Chief Financial Officer (Principal Financial Officer)
|
Signature
|
Title
|
Date
|
||
/s/ Srinidhi Devanur
|
Chairman of the Board and Director
|
March 25, 2020
|
||
Srinidhi Devanur
|
||||
/s/ Brent Kelton
|
Chief Executive Officer
|
March 25, 2020
|
||
Brent Kelton
|
||||
/s/ Barry Kostiner
|
Chief Financial Officer
|
March 25, 2020
|
||
Barry Kostiner
|
||||
/s/ Carmo Martella
|
Director
|
March 25, 2020
|
||
Carmo Martella
|
||||
/s/ Dimitrios Angelis
|
Director
|
March 25, 2020
|
||
Dimitrios Angelis
|
||||
/s/ Thoranath Sukumaran
|
Director
|
March 25, 2020
|
||
Thoranath Sukumaran
|
Subsidiary
|
Jurisdiction of Organization
|
Jurisdiction of Qualification
|
Ameri and Partners Inc.
|
Delaware
|
New Jersey, Kansas
|
Ameri100 Georgia Inc.
|
Georgia
|
N/A
|
Linear Logics, Corp.
|
Pennsylvania
|
N/A
|
AMERI100 Virtuoso Inc.
|
Delaware
|
Kansas
|
Ameri100 Arizona LLC
|
Arizona
|
N/A
|
Ameri100 California Inc.
|
Delaware
|
California, Texas, Louisiana
|
Ameri Consulting Services Private Ltd.
|
India
|
N/A
|
Bellsoft India Solutions Private Ltd.
|
India
|
N/A
|
Ameri100 Canada Inc.
|
Nova Scotia, Canada
|
N/A
|
Bigtech Software Private Limited
|
India
|
N/A
|
Date: March 25 , 2020
|
By:
|
/s/ Brent Kelton
|
|
Name:
|
Brent Kelton
|
||
Title:
|
Chief Executive Officer
(Principal Executive Officer)
|
Date: March 25, 2020
|
By:
|
/s/ Barry Kostiner
|
|
Name:
|
Barry Kostiner
|
||
Title:
|
Chief Financial Officer ( Principal Financial Officer)
|
Date: March 25, 2020
|
By:
|
/s/ Brent Kelton
|
|
Name:
|
Brent Kelton
|
||
Title:
|
Chief Executive Officer
(Principal Executive Officer)
|
Date: March 25, 2020
|
By:
|
/s/ Barry Kostiner
|
|
Name:
|
Barry Kostiner
|
||
Title:
|
Chief Financial Officer ( Principal Financial Officer)
|